Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Morris

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Molecular Psychiatry|April 16, 2021
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liabilityJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Neurotoxicology and Teratology|May 4, 2021
A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801Patrick J Morris, Richard D Burke, Alok K Sharma, et al.
Molecular Psychiatry|June 29, 2022
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive searchJordi Bonaventura, Juan L Gomez, Meghan L Carlton, et al.
Journal of Medicinal Chemistry|August 6, 2025
Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative MedicinePatrick J Morris, Damien Y Duveau, Michele Ceribelli, et al.
Translational Psychiatry|May 2, 2022
Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administrationRuin Moaddel, Panos Zanos, Cristan A Farmer, et al.
ACS Pharmacology & Translational Science|December 18, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) InhibitorsAna Corrionero, Xiaohu Zhang, Patricia Alfonso, et al.
The Journal of Experimental Medicine|July 13, 2018
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potentialSara E Meyer, David E Muench, Andrew M Rogers, et al.
Elife|October 3, 2017
Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancerVolkan I Sayin, Sarah E LeBoeuf, Simranjit X Singh, et al.
Nature|June 23, 2017
Zanos et al. replyPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Molecular Psychiatry|April 16, 2021
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liabilityJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Neurotoxicology and Teratology|May 4, 2021
A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801Patrick J Morris, Richard D Burke, Alok K Sharma, et al.
Molecular Psychiatry|June 29, 2022
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive searchJordi Bonaventura, Juan L Gomez, Meghan L Carlton, et al.
Journal of Medicinal Chemistry|August 6, 2025
Discovery and Optimization of LATS1 and LATS2 Kinase Inhibitors for Use in Regenerative MedicinePatrick J Morris, Damien Y Duveau, Michele Ceribelli, et al.
Translational Psychiatry|May 2, 2022
Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administrationRuin Moaddel, Panos Zanos, Cristan A Farmer, et al.
ACS Pharmacology & Translational Science|December 18, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) InhibitorsAna Corrionero, Xiaohu Zhang, Patricia Alfonso, et al.
The Journal of Experimental Medicine|July 13, 2018
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potentialSara E Meyer, David E Muench, Andrew M Rogers, et al.
Elife|October 3, 2017
Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancerVolkan I Sayin, Sarah E LeBoeuf, Simranjit X Singh, et al.
Nature|June 23, 2017
Zanos et al. replyPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Pageof 5